title: Should cost be considered in the overall evaluation of phase II clinical trials of new antineoplastic therapies? A response.
authors.affiliation: Medicine Branch, Division of Clinical Sciences, National Cancer Institute, Bethesda, Maryland 20892, USA.
authors.forename: E
authors.initials: E
authors.lastname: Reed
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic / Q000191:economics*; D004305:Dose-Response Relationship, Drug; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000191:economics; D017239:Paclitaxel / Q000191:economics / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D016179:Granulocyte Colony-Stimulating Factor; D017239:Paclitaxel